Anticoagulation After a Heart Attack with Left Ventricular Clot

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Left ventricular thrombus is a known complication after STEMI, and current evidence for anticoagulation largely comes from observational data. This interventional study compares adding rivaroxaban 15 mg to the usual dual antiplatelet therapy versus continuing dual antiplatelet therapy alone in patients with LVT detected by CMR or TTE. Eligible participants are within 7 days of STEMI and are on guideline-directed dual antiplatelet therapy; key exclusions include conditions requiring anticoagulation, pregnancy, significant organ dysfunction, or planned major cardiothoracic surgery. The trial aims to clarify whether adding anticoagulation improves outcomes without unacceptable bleeding risk. Primary results will inform management of LVT after STEMI and could influence guidelines if benefits outweigh harms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Established ST segment elevation myocardial infarction within 7 days Left ventricular thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE.

Ongoing treatment with dual anti-platelet therapy according to ESC/AHA guidelines at the time of randomization

Exclusion Criteria:

Clinically or hemodynamically unstable planed major surgeon such as CABG or Valve replacement within next 12 months Concomitant condition that requires anti- coagulation therapy, such as AF, DVT.

Any contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who is currently pregnant, or breastfeeding serious impaired renal and liver functions life expectancy less than 1 year can not provide consent

Where it's running

• Jilin university
  Changchun, Jilin, China Recruiting

Study contacts

• Principal investigator: Mingyou Zhang — The First Hospital of Jilin University
• Study coordinator: Mingyou Zhang
• Email: zmy@jlu.edu.cn
• Phone: 86-431-88782342

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Apixaban vs Warfarin for a Left Ventricular Thrombus

  This study tests whether apixaban can more conveniently and safely dissolve a left ventricular blood clot compared with warfarin.

  Recruiting Phase 3 University of Arizona · Tucson, Arizona · NCT07709780

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Using cardiac MRI and AI to predict outcomes after STEMI

  This project will try to use routine cardiac MRI scans plus AI to see if imaging features can predict long-term outcomes in people who had a STEMI treated with primary PCI.

  Recruiting Chinese PLA General Hospital · Beijing · NCT07072858

• Using beta-blockers for heart attack patients in intensive care

  This study is testing if the heart medication metoprolol can help heart attack patients in intensive care feel better and avoid worsening their condition.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT06967194

• Registry for patients with left ventricular thrombus

  This study is gathering information from people with blood clots in the heart to better understand the condition and improve treatment options.

  Recruiting at 5 sites Queen Mary University of London · Cambridge, Cambridgeshire and 7 other locations · NCT06963567

• Using an aspiration catheter for treating heart attacks

  This study tests whether using a special catheter can help remove blood clots from the heart arteries during a heart attack to improve blood flow and patient recovery.

  Recruiting BrosMed Medical Co., Ltd · Shanghai, Shanghai Municipality · NCT06951724

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.